menu
    • menu

    Company profile for Ovid Therapeutics

    NEW Drugs in Dev: 8
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndr...
    Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ovid TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    New York, NY 1460 Broadway New York, NY 10036
    Telephone
    Telephone
    (646) 661-7661
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ovidrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/10062052/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/OvidRx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ovid Therapeutics Prices $60M Private Placement
    Ovid Therapeutics Prices $60M Private Placement

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3257973/0/en/Ovid-Therapeutics-Announces-Pricing-of-60-Million-Private-Placement.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Ovid Therapeutics Announces OV329 Data, OV4071 Clearance
    Ovid Therapeutics Announces OV329 Data, OV4071 Clearance

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3257984/0/en/Ovid-Therapeutics-Announces-New-OV329-Data-and-Indication-Expansion-Phase-1-Clearance-for-OV4071-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Ovid Therapeutics To Participate In Upcoming Investor Conferences
    Ovid Therapeutics To Participate In Upcoming Investor Conferences

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244468/0/en/Ovid-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Ovid Therapeutics Reports Phase 1 Data for OV350 KCC2
    Ovid Therapeutics Reports Phase 1 Data for OV350 KCC2

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207665/0/en/Ovid-Therapeutics-Reports-Phase-1-Results-for-the-First-Ever-Direct-Activator-of-Potassium-Chloride-Cotransporter-2-KCC2-OV350-Intravenous-IV.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Ovid Pharma Names Dr. Petra Kaufmann Chief Medical Officer
    Ovid Pharma Names Dr. Petra Kaufmann Chief Medical Officer

    02 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/02/3197749/0/en/Ovid-Therapeutics-Appoints-Dr-Petra-Kaufmann-as-Chief-Medical-Officer.html

    GLOBENEWSWIRE
    02 Dec 2025
    Share Share
    Ovid Therapeutics Prices Private Placement Raising $175M
    Ovid Therapeutics Prices Private Placement Raising $175M

    03 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/03/3160890/0/en/Ovid-Therapeutics-Announces-Pricing-of-Private-Placement-Totaling-up-to-175-Million-in-Gross-Proceeds.html

    GLOBENEWSWIRE
    03 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search